If you’ve ever stood in the supplement aisle trying to decode a probiotic label — Lactobacillus acidophilus, Bifidobacterium longum, Saccharomyces boulardii — and wondered whether these names actually mean anything different or whether it’s just marketing variation, this guide is for you.
They do mean something different. Probiotic strains are not interchangeable. The evidence for Lactobacillus rhamnosus GG preventing antibiotic-associated diarrhea doesn’t transfer to Lactobacillus acidophilus for the same purpose. Saccharomyces boulardii can be taken alongside an antibiotic course without losing its effectiveness; most bacterial probiotics cannot. Bifidobacterium infantis 35624 has specific evidence for IBS bloating that random multi-strain formulas don’t replicate.
Understanding the major strains — what they do, what they’ve been studied for, and which situations they’re best suited to — is the most practical thing you can learn before buying a probiotic supplement.
Key Takeaways
- Probiotic effectiveness is strain-specific. The genus and species (e.g., Lactobacillus rhamnosus) tell you the category; the strain designation (e.g., GG) tells you what specific research exists for that organism.
- The three major probiotic genera in supplements are Lactobacillus (small intestine focus, lactic acid production), Bifidobacterium (large intestine focus, dominant in infants), and Saccharomyces (a yeast — fundamentally different from bacteria).
- S. boulardii probiotic is the only commonly used probiotic yeast. Its key advantage: it is unaffected by antibiotics, making it the logical choice for use during antibiotic treatment.
- KD 24: Saccharomyces boulardii benefits include antibiotic-associated diarrhea prevention, traveler’s diarrhea, and C. difficile recurrence reduction — all supported by randomized controlled trials.
- Bifidobacterium longum and Bifidobacterium breve have the lowest competitive content coverage of any major probiotic strains — and some of the clearest evidence for specific benefits.
- A single well-chosen strain at adequate CFU outperforms a generic 10-strain formula containing the wrong strains for your goal.
Why Strain Identity Is Everything in Probiotics
Before diving into individual strains, one concept is worth establishing clearly: in probiotic science, strain identity is the fundamental unit of evidence.
Consider an analogy. “Penicillin” covers dozens of different antibiotic compounds — penicillin V, amoxicillin, ampicillin — with meaningfully different spectrums of activity. Saying “penicillin works for this infection” doesn’t tell you which specific compound to use. Probiotics work the same way.
When a clinical trial finds that Lactobacillus rhamnosus GG reduces antibiotic-associated diarrhea, that finding applies specifically to the GG strain of L. rhamnosus. A different strain of L. rhamnosus — say, L. rhamnosus LC705 — has different documented properties. The genus and species tell you the general category; the strain identifier (GG, LC705, 35624, NCFM) tells you what specific research exists.
This is why “contains Lactobacillus” on a label is meaningful but incomplete. Which Lactobacillus? Which strain? Is there published research on that strain for what you’re trying to address?
With that framework established, here’s a practical guide to the major probiotic genera and their most studied strains.
S. Boulardii Probiotic: The Yeast That Antibiotics Can’t Kill
Saccharomyces boulardii is categorically different from every other common probiotic — it’s a yeast, not a bacterium. This distinction has one profoundly practical implication: antibiotics don’t kill it.
Antibiotics work by targeting bacterial cellular structures — cell walls, ribosomes, DNA replication machinery. Yeast (fungi) have completely different cellular architecture. When you take an antibiotic that’s systematically disrupting your gut bacteria, S. boulardii continues functioning normally. This makes it uniquely suited for use during antibiotic treatment — not just after.
Saccharomyces Boulardii Benefits
Antibiotic-associated diarrhea prevention: This is the most consistently supported use. A 2017 Cochrane review of 31 trials found that S. boulardii significantly reduced the risk of antibiotic-associated diarrhea. The protective effect was present in both children and adults, and the timing matters: starting within the first 2 days of antibiotic treatment produces the best results.
Traveler’s diarrhea: Multiple trials have found S. boulardii reduces the incidence and duration of traveler’s diarrhea. A meta-analysis found a 28% relative risk reduction in adults taking S. boulardii prophylactically while traveling to high-risk regions.
C. difficile recurrence reduction: Clostridioides difficile (C. diff) is a serious gut infection that often occurs after antibiotic courses and has a high recurrence rate. S. boulardii produces proteases that cleave C. diff toxins and has been shown in several trials to significantly reduce C. diff recurrence when used alongside standard antibiotic treatment.
Mechanism: S. boulardii works through several pathways — producing proteases that neutralize bacterial toxins, secreting IgA antibodies that block pathogen adherence, competing with pathogens for intestinal colonization sites, and reducing gut inflammation via inhibition of NF-κB signaling.
Saccharomyces Boulardii Uses: Practical Guidance
During antibiotic courses: Take S. boulardii at the same time as your antibiotic — there’s no need to space them apart, as the antibiotic won’t affect a yeast. Continue for 1–2 weeks after finishing the course.
For traveler’s diarrhea prevention: Start 5 days before travel and continue throughout the trip. Standard doses in trials: 250–500 mg daily (containing approximately 5 billion CFU).
Storage note: Some S. boulardii products require refrigeration; others are shelf-stable. Check the label. Shelf-stable versions typically use lyophilized (freeze-dried) cultures that are more resistant to temperature variation.
Who should not take it: People with fungal allergies, seriously immunocompromised individuals (risk of fungemia — yeast entering the bloodstream), or anyone with a central venous catheter. For healthy adults, the safety profile is excellent.
Lactobacillus Strains: Small Intestine Specialists
Lactobacillus bacteria are the most numerous genus in most commercial probiotic products. They primarily colonize the small intestine and produce lactic acid — which lowers intestinal pH and creates an inhospitable environment for many pathogens. Several species have been reclassified in recent years (Lacticaseibacillus, Limosilactobacillus), but most supplement labels still use the historical Lactobacillus naming.
Lactobacillus Rhamnosus GG: The Most Studied Probiotic in the World
L. rhamnosus GG (the GG designation comes from its discoverers, Gorbach and Goldin) holds a unique position in probiotic research — it has more published clinical trials than any other probiotic strain. Key documented effects:
Acute infectious diarrhea: A meta-analysis of 11 trials found L. rhamnosus GG reduced the duration of acute diarrhea by approximately 1.1 days. The effect is most consistent in children with rotavirus-associated diarrhea.
Antibiotic-associated diarrhea: Multiple trials support L. rhamnosus GG for reducing antibiotic-associated diarrhea — though it must be taken apart from the antibiotic dose (minimum 2 hours), unlike S. boulardii.
Respiratory infections in children: Several trials found that children taking L. rhamnosus GG had fewer and shorter respiratory infections compared to placebo — one of the better-supported immune benefits in pediatric probiotic research.
Lactobacillus Reuteri Benefits
L. reuteri produces reuterin — a broad-spectrum antimicrobial compound — as well as bacteriocins that inhibit pathogen growth. Key uses:
Infant colic: The most consistently supported evidence for L. reuteri DSM 17938 specifically. Multiple trials found that breastfed infants with colic who received L. reuteri cried significantly less (in one trial, 47 minutes/day vs 95 minutes/day in placebo). This doesn’t work for formula-fed infants as consistently.
H. pylori eradication support: L. reuteri as an adjunct to antibiotic treatment for Helicobacter pylori has been shown in several trials to improve eradication rates and reduce antibiotic side effects.
Dental health: L. reuteri produces antimicrobial compounds that reduce Streptococcus mutans (the primary cariogenic bacterium) in the oral microbiome. A few small trials have shown reductions in dental caries risk.
Lactobacillus Plantarum Benefits
L. plantarum is one of the most versatile and environmentally resilient Lactobacillus species — it survives a wider range of conditions (temperature, pH, oxygen levels) than most probiotics, making it stable in various supplement formulations and in fermented foods.
IBS symptom management: L. plantarum 299v has the most specific evidence for IBS, with multiple trials showing reductions in abdominal pain, bloating, and flatulence. A key 2012 trial found significant improvement in abdominal pain scores compared to placebo over 4 weeks.
Gut barrier function: L. plantarum has documented effects on tight junction proteins — the structures that maintain intestinal permeability and prevent bacterial products from crossing into the bloodstream. This “leaky gut” protective mechanism has implications beyond IBS, including inflammatory conditions.
Post-antibiotic recovery: L. plantarum‘s resilience makes it useful for microbiome restoration after antibiotic courses, particularly when combined with Bifidobacterium strains.
Lactobacillus Gasseri Benefits
L. gasseri is one of the dominant Lactobacillus species in the healthy vaginal microbiome, and it’s received attention for both vaginal health and metabolic research.
Vaginal microbiome support: L. gasseri produces lactic acid and hydrogen peroxide that inhibit pathogens including Candida and Gardnerella vaginalis (associated with bacterial vaginosis). Some evidence that oral supplementation with L. gasseri can restore vaginal Lactobacillus populations.
Body composition: Several Japanese trials found modest reductions in visceral fat with L. gasseri SBT2055 supplementation over 12 weeks. The effect size is real but small, and these results have not been consistently replicated across populations.
Lactobacillus Acidophilus Benefits
L. acidophilus NCFM is one of the most common strains in commercial probiotic products. Documented uses include improving lactose digestion symptoms (particularly for people with lactose intolerance), supporting general gut health, and modest immune support. It’s a well-tolerated, broadly applicable strain without dramatic specific effects in any one area.
Lactobacillus Casei Benefits
L. casei Shirota (found in Yakult) has the most published evidence in a yogurt drink format. Key documented effects: reduction in antibiotic-associated diarrhea in hospitalized patients, improvements in gut transit time, and modest immune function support in clinical settings.
Bifidobacterium Strains: Large Intestine Specialists
Bifidobacterium bacteria dominate the healthy infant gut microbiome — in breastfed infants, they can comprise up to 90% of fecal bacteria. In adults, Bifidobacterium populations decline with age and with antibiotic exposure. These bacteria are particularly active in the colon, fermenting dietary fiber into short-chain fatty acids (SCFAs) that nourish colon cells and regulate immune function.
Bifidobacterium Longum Benefits
B. longum is one of the most abundant Bifidobacterium species in the adult gut and one of the most studied for specific health outcomes.
IBS and constipation: B. longum has specific evidence for constipation-predominant IBS and functional constipation. A well-designed trial found B. longum 1714 significantly reduced bowel discomfort, frequency, and transit time in people with functional gut symptoms.
Stress and cognitive function: B. longum 1714 has been studied in healthy adults for effects on stress resilience and cognitive performance. A 2019 trial found improvements in several stress biomarkers and self-reported anxiety scores. This sits in the “emerging evidence” category — the gut-brain axis mechanism is well-established; the clinical magnitude for psychological outcomes is still being characterized.
Immune modulation: B. longum BORI (and related strains) has shown reductions in respiratory infection frequency in some trials, and improvements in vaccine antibody responses — suggesting a role in immune priming.
Bifidobacterium Breve Benefits
B. breve is particularly abundant in the infant gut and has been studied for both infant and adult health outcomes.
Infant gut development and eczema prevention: B. breve M-16V has been studied in preterm infants and full-term infants for gut microbiome establishment. Evidence suggests early B. breve colonization may reduce the risk of eczema in high-risk infants.
Adult gut health: B. breve Yakult has evidence for improving stool consistency and reducing IBS symptoms in adults. Its high β-galactosidase activity makes it useful for improving lactose digestion.
Metabolic effects: Some trials have found modest reductions in body fat percentage with B. breve supplementation, though the effect size is small and more research is needed.
Bifidobacterium Lactis Benefits
B. animalis subsp. lactis (often labeled simply as B. lactis) is found in several commercial yogurt products including Activia. It’s one of the more resilient Bifidobacterium strains — survives commercial processing and gastrointestinal transit well.
Gut transit time: B. lactis DN-173 010 (the Activia strain) has documented evidence for improving gut transit time and reducing functional constipation symptoms. Multiple trials over 2–4 weeks showed meaningful improvements in stool frequency and consistency.
Immune function: B. lactis Bl-04 has some of the stronger immune evidence for a Bifidobacterium strain — trials in adults found reductions in respiratory infection incidence and duration.
Bifidobacterium Infantis Benefits
B. infantis 35624 (marketed as Align) has the most specifically studied evidence for IBS among all probiotic strains. A landmark trial found significant improvements in IBS symptom scores — bloating, abdominal pain, bowel urgency — with B. infantis 35624 compared to placebo. This strain is the closest thing to a strain-specific recommendation for IBS currently available.
Bifidobacterium Bifidum Benefits
B. bifidum is dominant in breastfed infants and plays a key role in metabolizing human milk oligosaccharides. In adults, it has evidence for supporting respiratory immunity and, in combination with other Bifidobacterium strains, for reducing traveler’s diarrhea incidence.
Choosing the Right Probiotic Strain: A Decision Framework
| Your Goal | Best-Evidenced Strain | Dose Used in Research |
|---|---|---|
| Antibiotic-associated diarrhea | S. boulardii (during antibiotics) or L. rhamnosus GG (2h apart from antibiotic) | 250–500 mg or 10B CFU |
| IBS bloating and pain | B. infantis 35624 or L. plantarum 299v | 1–10B CFU |
| Acute infectious diarrhea | L. rhamnosus GG | 10B CFU |
| Traveler’s diarrhea prevention | S. boulardii | 250–500 mg daily |
| Infant colic | L. reuteri DSM 17938 | 100M CFU drops |
| Constipation / slow transit | B. lactis DN-173 010 | 10B CFU |
| Post-antibiotic recovery | L. rhamnosus GG + B. longum | 10–50B CFU combined |
| Vaginal microbiome support | L. rhamnosus GR-1 + L. reuteri RC-14 | 1B CFU each |
| Eczema (infants, prevention) | L. rhamnosus GG or B. breve M-16V | 10B CFU |
| Gut-brain / stress resilience | B. longum 1714 | 1–10B CFU |
Single Strain vs Multi-Strain Probiotics: Which Is Better?
This is a question without a universal answer — the research supports both approaches depending on the goal.
Single-strain products are better for: Conditions with strain-specific evidence (B. infantis 35624 for IBS; L. rhamnosus GG for AAD; S. boulardii for traveler’s diarrhea). When you know the specific strain that has been studied for your situation, a single-strain product ensures you’re getting that strain at adequate CFU.
Multi-strain products may be better for: General microbiome support and diversity (where no single strain has been specifically studied), post-antibiotic recovery (broader microbiome restoration), and situations where your goal is less condition-specific.
The practical consideration: multi-strain products often spread CFU across strains, meaning each individual strain may be present at lower doses than the amounts used in research. A product that claims “10 billion CFU” split across 10 strains contains 1 billion CFU of each — which is lower than the doses used in most research.
Frequently Asked Questions
What is S. boulardii probiotic used for? Saccharomyces boulardii is primarily used for antibiotic-associated diarrhea prevention, traveler’s diarrhea, and reducing C. difficile recurrence. Its key advantage is that it’s a yeast — antibiotics targeting bacteria don’t affect it, so it can be taken simultaneously with antibiotic treatment without losing effectiveness.
What are the saccharomyces boulardii benefits? The most evidence-supported benefits are: reducing antibiotic-associated diarrhea risk (by approximately 51% per Cochrane review data), shortening traveler’s diarrhea duration, and reducing C. difficile recurrence when used alongside antibiotic treatment. It also has some evidence for general gut microbiome support and reducing gut inflammation.
What are the bifidobacterium longum benefits? B. longum has documented benefits for IBS (particularly constipation-predominant), functional constipation, stress resilience and cognitive function (via the gut-brain axis), and immune modulation. B. longum 1714 is the most studied strain for gut-brain outcomes; B. longum BORI has the strongest immune evidence.
What are the lactobacillus plantarum benefits? L. plantarum 299v has the strongest specific evidence for IBS symptom management (abdominal pain, bloating) among Lactobacillus strains for this condition. It also supports gut barrier integrity through effects on tight junction proteins and is used for post-antibiotic recovery due to its environmental resilience.
Which probiotic strain is best for IBS? Bifidobacterium infantis 35624 (sold as Align) has the most specific and consistent evidence for IBS across bloating, abdominal pain, and bowel urgency. Lactobacillus plantarum 299v is the second-strongest for IBS abdominal pain specifically. Multi-strain products containing B. infantis and L. plantarum may offer broader symptom coverage.
Can I take S. boulardii with antibiotics? Yes — and this is its key advantage. Because S. boulardii is a yeast (fungus) rather than a bacterium, antibiotics that target bacterial cellular structures don’t affect it. It can be taken simultaneously with the antibiotic dose without any interaction concern. Bacterial probiotic strains like L. rhamnosus GG should be taken at least 2 hours away from antibiotic doses.
The Bottom Line
Probiotic strains are not interchangeable, and the label matters. Saccharomyces boulardii is the rational choice when you need a probiotic that can be taken alongside antibiotics — its yeast biology makes it uniquely antibiotic-resistant. For IBS, B. infantis 35624 has the most specific evidence. For post-antibiotic recovery, combining L. rhamnosus GG with Bifidobacterium strains covers the most ground.
The most useful skill when buying a probiotic: look past the total CFU number and marketing claims, find the Supplement Facts panel, identify the specific strain names listed, and check whether those strains have published research for your situation.
Want to understand how much CFU you need and when to take your probiotic for best absorption? What Are Probiotics? Strains, CFU, and How They Actually Work (C1)
Looking for a complete guide to probiotic benefits by condition — including which goals have strong evidence vs. weak? Probiotic Benefits: What the Research Actually Shows (C2)
References
- Goldenberg JZ, Yap C, Lytvyn L, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database of Systematic Reviews. 2017;(12):CD006095. doi:10.1002/14651858.CD006095.pub4
- McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World Journal of Gastroenterology. 2010;16(18):2202-2222. doi:10.3748/wjg.v16.i18.2202
- Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2018;48(10):1044-1060. doi:10.1111/apt.15001
- National Institutes of Health Office of Dietary Supplements. Probiotics: Fact Sheet for Health Professionals. Updated June 2026. https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/
- Hill C, Guarner F, Reid G, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology. 2014;11(8):506-514. doi:10.1038/nrgastro.2014.66